Theravance Announces Positive Phase 2 Clinical Results in the MABA Respiratory...
Marketwire via Yahoo! Finance: 4 views since Monday, July 14, 2008 at 04:05 PM
Theravance, Inc. announced today the positive results from a Phase 2 study of the lead investigational compound GSK961081 in the inhaled bifunctional muscarinic antagonist-beta2 agonist program.

Published in: Randomized Things